Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Children With Relapsed or Refractory Solid Tumors
NCT02011126Phase 2Withdrawn
- Sponsor
- Children's Oncology Group
- Start
- Jun 2014
- Primary completion
- Mar 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
A Phase 2 trial of imetelstat in osteosarcoma (OS), Ewing sarcoma, rhabdomyosarcoma (RMS), neuroblastoma, hepatoblastoma, sponsored by Children's Oncology Group. Planned start Jun 2014; status: withdrawn.
02
Drugs
imetelstat
03
Conditions
osteosarcoma (OS)Ewing sarcomarhabdomyosarcoma (RMS)neuroblastomahepatoblastoma
Beyond the preview
Go deeper on NCT02011126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011126.